Moderna says RSV vaccine is 84% effective at preventing disease in older adults

Moderna says RSV vaccine is 84% effective at preventing disease in older adults


A woman receives a booster dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination centre in Antwerp, Belgium, February 1, 2022.

Johanna Geron | Reuters

Moderna on Tuesday said its vaccine targeting respiratory syncytial virus is effective at preventing disease in older adults.

The vaccine was 83.7% effective at preventing lower respiratory tract disease, defined as two or more symptoms, in people ages 60 and older, according to the Boston biotech company. It was 82.4% effective at preventing lower respiratory tract disease with three or more symptoms.

No safety concerns have been identified during the clinical trial of the vaccine, according to Moderna. The safety and efficacy data from the trial will be published in a peer-reviewed journal, according to the company. The clinical trial has enrolled about 37,000 people across 22 countries.

Moderna said it plans to file an application for approval by the Food and Drug Administration in the first half of this year. There currently is no FDA-approved vaccine for RSV.

Moderna’s stock rose nearly 7% in extended trading.

RSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the Centers for Disease Control and Prevention.

The U.S. suffered an unusually severe RSV season last fall among children and older adults as the public largely stopped practicing public health measures implemented in response to the Covid-19 pandemic, such as masking and social distancing.

Moderna’s RSV vaccine uses the same messenger RNA technology as the company’s successful Covid shots. The Covid vaccine turned Moderna into a global name and delivered windfall profits, but it remains the company’s only commercially available product and demand is fading.

The Boston biotech company faces growing pressure to demonstrate that other products in its pipeline will successfully come to market. Morgan Stanley estimates the market for an adult RSV vaccine is $7 billion to $10 billion.

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

CDC Director Susan Monarez ousted, four other leaders quit health agency
Health

CDC Director Susan Monarez ousted, four other leaders quit health agency

Susan Monarez, President Donald Trump’s nominee to be the Director of the Centers for Disease Control and Prevention (CDC), testifies during her confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions in the Dirksen Senate Office Building on June 25, 2025 in Washington, DC. Kayla Bartkowski | Getty Images Centers for Disease […]

Read More
FDA approves new Covid shots with limits on who can get them, as RFK Jr. changes vaccine precedents
Health

FDA approves new Covid shots with limits on who can get them, as RFK Jr. changes vaccine precedents

Pfizer’s Covid vaccine Comirnaty, seen at a CVS Pharmacy in Eagle Rock, California, Sept. 14, 2023. Irfan Khan | Los Angeles Times | Getty Images The Food and Drug Administration on Wednesday approved the latest round of Covid vaccines in the U.S., but set new limits on who can get them. The agency ended its […]

Read More
Healthy Returns: Eli Lilly’s chief scientific officer breaks down the latest obesity pill data
Health

Healthy Returns: Eli Lilly’s chief scientific officer breaks down the latest obesity pill data

The Eli Lilly headquarters in Indianapolis, Indiana, on Aug. 15, 2024. AJ Mast | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Eli Lilly‘s closely watched obesity pill is inching closer […]

Read More